IMC Chicago’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.7K Buy
17,900
+3,900
+28% +$4.63K ﹤0.01% 6274
2026
Q1
$24.4K Buy
+14,000
New +$23K ﹤0.01% 5620
2022
Q1
– Sell
-8,800
Closed -$527K – 1151
2021
Q4
$527K Sell
8,800
-5,458
-38% -$437K ﹤0.01% 1091
2021
Q3
$1.23M Sell
14,258
-5,184
-27% -$520K ﹤0.01% 948
2021
Q2
$2.16M Sell
19,442
-13,166
-40% -$1.26M ﹤0.01% 766
2021
Q1
$3.63M Buy
32,608
+3,816
+13% +$502K 0.01% 632
2020
Q4
$3.06M Sell
28,792
-19,166
-40% -$2.55M ﹤0.01% 647
2020
Q3
$6.68M Buy
47,958
+23,591
+97% +$4.92M 0.01% 376
2020
Q2
$7.88M Buy
+24,367
New +$3.91M 0.02% 298

Other funds holding INO

IMC Chicago's INO Position: Q2 2026 in Review

IMC Chicago sold out of Inovio Pharmaceuticals (INO) in Q2 2026, closing a stake of 37,889 shares — an estimated $45K sold.

IMC Chicago first reported a position in INO in Q2 2020 and held it in 3 quarters. The position peaked at $719K in Q2 2020. 102 funds tracked by Wall St. Rank hold INO as of Q2 2026.

  • IMC Chicago reported no remaining Inovio Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 37,889 Inovio Pharmaceuticals shares in Q2 2026, an estimated $45K.
  • IMC Chicago first reported a position in Inovio Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • IMC Chicago's Inovio Pharmaceuticals position peaked at $719K in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.